Phospho-CEP55 (S425) Antibody

What is the biological significance of CEP55 phosphorylation at Ser425?

Phosphorylation of CEP55 at Ser425 is a critical regulatory event in cell division. This post-translational modification is performed by Cyclin-dependent kinase 1 (Cdk1) during early mitosis and functions within a hierarchical phosphorylation cascade. Specifically, both Ser425 and Ser428 become phosphorylated at the onset of mitosis, preceding the phosphorylation of Ser436 by Polo-like kinase 1 (PLK1). The phosphorylation at Ser425 and Ser428 is essential for CEP55 dissociation from the centrosome at the G2/M boundary, allowing its redistribution during cell division. Without these phosphorylation events, CEP55 cannot properly relocalize from the centrosome to the midbody, which impairs cytokinesis . This hierarchical phosphorylation mechanism (S425/S428 followed by S436) ensures proper timing of CEP55 functions throughout mitosis and cytokinesis.

How does CEP55 function change when phosphorylated at Ser425?

When phosphorylated at Ser425, CEP55 undergoes a significant functional transition. In its unphosphorylated state, CEP55 is concentrated at centrosomes during interphase. Upon phosphorylation at Ser425 (along with S428) at the onset of prophase, CEP55 is released from centrosomes and follows a precise trafficking pattern: it moves sequentially to spindle pole regions (late prophase), to the mitotic spindle (metaphase), to the spindle midzone (anaphase), and finally assembles into a ring within the Flemming body during cytokinesis . This phosphorylation-dependent relocalization is crucial for CEP55's ability to recruit essential abscission factors including members of the ESCRT machinery to the midbody. Without proper phosphorylation, CEP55 remains abnormally localized, leading to failures in the final stages of cell division . The phosphorylation at Ser425 therefore acts as a molecular switch that converts CEP55 from a centrosomal protein to a key midbody organizer.

What experimental methods can confirm the specificity of Phospho-CEP55 (S425) antibody?

To rigorously confirm antibody specificity, researchers should implement a multi-method validation approach:

• Phosphatase treatment validation: Treat one sample with lambda phosphatase before immunoblotting to demonstrate signal loss, confirming phosphorylation-specific detection.

• Phospho-mutant controls: Express CEP55 with S425A mutation (preventing phosphorylation) and compare with wild-type CEP55 under conditions promoting phosphorylation.

• Phospho-peptide competition assay: Pre-incubate the antibody with phosphorylated and non-phosphorylated peptides containing the S425 site, and observe selective blocking of signal with the phospho-peptide.

• Sequential chromatography validation: Some commercial antibodies (like Affinity Biosciences #AF8254) are validated using sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns, ensuring selective binding to the phosphorylated form .

• Cell cycle-dependent detection: Since CEP55 S425 phosphorylation occurs during mitosis, comparing synchronized cell populations at different cell cycle stages should show signal variability consistent with known phosphorylation timing .

What are the optimal conditions for detecting phosphorylated CEP55 (S425) in Western blot applications?

For optimal detection of phosphorylated CEP55 (S425) in Western blot applications, researchers should implement the following protocol:

• Sample preparation:

  • Use phosphatase inhibitors (including sodium fluoride, sodium orthovanadate, and β-glycerophosphate) in cell lysis buffers

  • Include proteasome inhibitors (e.g., MG132 at 5 μM) if studying protein stability

  • Extract protein from mitotic-enriched cells (e.g., nocodazole or thymidine block release)

• Electrophoresis and transfer:

  • Use freshly prepared SDS-PAGE gels (8-10%) for optimal separation of the 54-55 kDa CEP55 protein

  • Transfer at lower voltage (e.g., 30V overnight at 4°C) to ensure complete transfer of larger proteins

• Antibody incubation:

  • Block with 5% BSA (not milk) in TBST to prevent phospho-epitope masking

  • Dilute primary antibody at 1:500-1:2000 as recommended by manufacturers

  • Incubate at 4°C overnight with gentle agitation

  • For visualization, HRP-conjugated secondary antibodies at 1:5000-1:10000 are typically effective

• Controls:

  • Include both phosphatase-treated samples and cell cycle-synchronized positive controls

  • If available, include recombinant phosphorylated and non-phosphorylated CEP55 as standards

• Expected results:

  • Phospho-CEP55 (S425) appears as a distinct band at approximately 54-55 kDa

  • Signal intensity should correlate with mitotic index in your samples

How can researchers effectively use Phospho-CEP55 (S425) antibody in immunofluorescence studies of cell division?

For effective immunofluorescence studies tracking CEP55 phosphorylation throughout cell division:

• Cell preparation and fixation:

  • Grow cells on coated coverslips to subconfluent density

  • Fix with 4% paraformaldehyde (10 min) followed by permeabilization with 0.2% Triton X-100 (5 min)

  • For better preservation of centrosomal structures, consider methanol fixation (-20°C, 10 min)

• Antibody staining:

  • Block with 3% BSA in PBS (1 hour at room temperature)

  • Dilute Phospho-CEP55 (S425) antibody at 1:50-1:200 range as recommended

  • Co-stain with cell cycle markers (e.g., pH3 for mitotic cells) and structural markers:

    • α-tubulin for microtubules

    • γ-tubulin for centrosomes

    • Aurora B for midbody identification

• Visualization strategy:

  • Use confocal microscopy for optimal resolution of centrosomal and midbody structures

  • Acquire z-stacks (0.3-0.5 μm steps) for complete structural visualization

  • For dynamic studies, consider time-lapse imaging with stable cell lines expressing fluorescently tagged CEP55

• Expected localization patterns:

  • Interphase: Minimal phospho-S425 signal, with total CEP55 at centrosomes

  • Prophase: Increasing phospho-S425 signal as CEP55 begins dissociating from centrosomes

  • Metaphase: Diffuse cytoplasmic and spindle-associated phospho-S425 signal

  • Anaphase: Enrichment at the spindle midzone

  • Telophase/Cytokinesis: Strong signal at the midbody

• Validation controls:

  • Include cells treated with CDK1 inhibitors (e.g., RO-3306) to demonstrate phosphorylation-dependent localization

  • Consider siRNA knockdown of CEP55 followed by rescue with wild-type or S425A mutant constructs

This methodology allows researchers to track the dynamic phosphorylation and localization changes of CEP55 throughout cell division .

What controls should be included when studying CEP55 S425 phosphorylation in relation to cell cycle progression?

A comprehensive control strategy for studying CEP55 S425 phosphorylation throughout the cell cycle should include:

• Cell synchronization controls:

  • Thymidine block (G1/S boundary)

  • RO-3306 treatment (G2/M boundary)

  • Nocodazole arrest (prometaphase)

  • Synchronized release time course sampling

• Kinase manipulation controls:

  • CDK1 inhibition (e.g., with BI 2536 at 3 nM) to prevent S425 phosphorylation

  • PLK1 inhibition to examine hierarchical phosphorylation effects

  • Compare against other cell cycle-regulated phosphorylation events (e.g., Histone H3-S10)

• Genetic controls:

  • CEP55 wild-type overexpression

  • Phospho-mutants (S425A, S428A, and S436A single and combination mutants)

  • Phospho-mimetic mutants (S425D/E)

• Cytological markers:

  • Co-staining for:

    • Cyclins (A, B) to mark cell cycle phases

    • pH3 to identify mitotic cells

    • PCNA for S-phase cells

    • Centrosomal markers (γ-tubulin)

    • Midbody markers (Aurora B)

• Technical controls:

  • Phosphatase treatment of samples to eliminate phospho-specific signals

  • λ-phosphatase-treated lysates as negative controls

  • Peptide competition assays using phospho and non-phospho peptides

By implementing these controls, researchers can definitively correlate CEP55 S425 phosphorylation with specific cell cycle phases and mechanistically understand its regulation and function .

How does phosphorylation of CEP55 at S425 relate to its role in microtubule stabilization and chromosomal instability?

The relationship between CEP55 S425 phosphorylation and its function in microtubule stabilization reveals a complex regulatory mechanism affecting chromosomal stability:

• Direct effects on microtubule dynamics:
  Recent research demonstrates that CEP55 functions as a microtubule-stabilizing protein, with significant effects on microtubule dynamics. In vitro experiments show that CEP55 protects microtubules from cold-induced depolymerization by approximately 80% and increases the rate of microtubule polymerization 4-fold . This stabilization function appears to be independent of microtubule nucleation, suggesting CEP55 primarily attenuates microtubule depolymerization.

• Phosphorylation-dependent localization affecting spindle function:
  Phosphorylation at S425 (along with S428) by CDK1 is required for CEP55 dissociation from centrosomes at the G2/M boundary . This relocalization is crucial for proper spindle formation and function. When CEP55 is depleted, studies show reduced fraction of stable spindle microtubules . Conversely, high CEP55 levels increase microtubule stability but paradoxically promote chromosomal instability (CIN).

• Mechanistic link to chromosomal instability:
  The connection between CEP55 phosphorylation and chromosomal instability appears to involve a balance in microtubule dynamics:

  • High levels of CEP55 increase the frequency of misaligned and missegregated chromosomes

  • This correlates with increased micronuclei formation and heterogeneity in chromosome numbers

  • The effect depends on direct microtubule binding, as mutants lacking microtubule-binding domains (CEP55 59-428) fail to induce CIN

• Phosphorylation-mediated temporal regulation:
  The timing of CEP55 phosphorylation at S425 likely ensures that its microtubule-stabilizing activity is properly regulated throughout mitosis. Improper phosphorylation could disrupt the precise balance of microtubule dynamics required for accurate chromosome segregation.

This evidence suggests a model where phosphorylation of CEP55 at S425 serves as a molecular switch controlling not only its localization but also its functional interactions with the microtubule cytoskeleton, with direct consequences for chromosomal stability .

What is the relationship between CEP55 S425 phosphorylation and the ESCRT machinery recruitment during cytokinesis?

The relationship between CEP55 S425 phosphorylation and ESCRT machinery recruitment represents a critical regulatory mechanism in cytokinesis:

• Phosphorylation-dependent sequential localization:
  CEP55 phosphorylation at S425 (along with S428) by CDK1 at the onset of mitosis initiates a precisely timed translocation sequence. This phosphorylation triggers CEP55 release from centrosomes, allowing it to progress through defined cellular locations: spindle poles (late prophase), mitotic spindle (metaphase), spindle midzone (anaphase), and finally the midbody/Flemming body during cytokinesis . This phosphorylation-dependent trafficking ensures CEP55 arrives at the midbody at the correct time to orchestrate abscission.

• Direct ESCRT component interactions:
  Research shows that CEP55 directly interacts with multiple ESCRT pathway components through specific binding domains:

  • CEP55 contains two NEMO-like ubiquitin-binding domains that mediate interactions with ESCRT proteins

  • Direct two-hybrid interactions have been demonstrated between CEP55 and HRS/ESCRT-0, TSG101/ESCRT-I, VPS37/ESCRT-I, and ALIX

  • These interactions are essential for recruiting ESCRT-III components (including CHMP4 proteins) to the midbody

• Hierarchical regulation with PLK1:
  While S425 phosphorylation initiates CEP55 relocalization, a subsequent phosphorylation at S436 by PLK1 regulates the timing of CEP55 accumulation at the midbody. This PLK1-mediated phosphorylation prevents premature CEP55 recruitment to the midbody and is essential for proper recruitment of ESCRT machinery . Impairment of this PLK1 phosphorylation leads to severe abscission defects.

• Functional consequences for abscission:
  The properly phosphorylated CEP55 at the midbody acts as a molecular platform for ESCRT recruitment:

  • It recruits ALIX and TSG101 (ESCRT-I) through direct interactions

  • This triggers the sequential recruitment of ESCRT-III subunits to the midbody

  • VPS4A (an ESCRT-associated ATPase) is subsequently recruited

  • Without proper CEP55 phosphorylation and localization, this recruitment cascade fails

This phosphorylation-regulated process ensures proper spatial and temporal coordination of ESCRT machinery assembly at the midbody, which is essential for the final membrane scission event in cytokinesis .

How does the hierarchical phosphorylation of CEP55 (S425, S428, and S436) coordinate its functions during cell division?

The hierarchical phosphorylation of CEP55 at residues S425, S428, and S436 creates a sophisticated temporal control system that coordinates distinct aspects of CEP55 function throughout cell division:

• Sequential phosphorylation timing:

  • S425 and S428 are phosphorylated first, at the onset of mitosis by CDK1 and ERK2 respectively

  • S436 phosphorylation by PLK1 occurs later, after the initial phosphorylation events
    This sequential pattern creates a multi-step activation process for CEP55.

• Distinct functional transitions controlled by different phosphorylation events:

  • S425/S428 phosphorylation primarily controls centrosomal dissociation:

    • These modifications are required for CEP55 to dissociate from the centrosome at the G2/M boundary

    • Without these initial phosphorylation events, CEP55 remains inappropriately localized at centrosomes

  • S436 phosphorylation primarily regulates midbody recruitment timing:

    • This later modification prevents premature recruitment of CEP55 to the mitotic spindle

    • It controls the precise timing of CEP55 accumulation at the midbody

    • Impairment of S436 phosphorylation leads to severe abscission defects and inhibition of ESCRT machinery recruitment

• Coordinated phosphorylation effects on protein-protein interactions:
  The hierarchical phosphorylation pattern affects CEP55's interaction network:

  • Initial S425/S428 phosphorylation may alter conformation to expose binding sites for midbody-associated proteins

  • S436 phosphorylation fine-tunes interactions with binding partners including MTMR3 and MTMR4 (Myotubularin-related proteins 3 and 4), which indirectly mediate PLK1 association

  • Together, these modifications orchestrate the assembly of the abscission machinery

• Pathological consequences of disrupted phosphorylation hierarchy:
  Interference with this phosphorylation pattern has severe consequences:

  • Deletion of the C-terminal region containing S436 is associated with MARCH syndrome (multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly)

  • Dysregulation of this phosphorylation cascade in cancer cells contributes to cytokinesis defects and chromosomal instability

This phosphorylation hierarchy thus acts as a molecular timer, ensuring that CEP55's multiple functions occur in the precise sequence required for successful cell division .

What strategies can resolve inconsistent detection of phosphorylated CEP55 (S425) in experimental samples?

Inconsistent detection of phosphorylated CEP55 (S425) can be addressed through this systematic troubleshooting framework:

• Sample preparation optimization:

  • Phosphatase inhibition: Ensure comprehensive phosphatase inhibitor cocktails are used (including sodium fluoride, sodium orthovanadate, β-glycerophosphate, and calyculin A)

  • Rapid processing: Minimize time between cell harvesting and protein denaturation

  • Lysis buffer optimization: Test different lysis buffers (RIPA vs. NP-40 based) as the phospho-epitope may be better preserved in one formulation

  • Protein extraction temperature: Perform all extraction steps at 4°C with pre-chilled reagents

• Cell cycle synchronization approaches:

  • Enrichment for mitotic cells: Since S425 phosphorylation occurs during mitosis, synchronize cells using:

    • Nocodazole (100 ng/ml) for prometaphase arrest

    • Double thymidine block and release for early mitotic enrichment

    • Mitotic shake-off to collect actively dividing cells

  • Cell cycle validation: Always verify cell cycle distribution by flow cytometry or mitotic index count

• Antibody optimization:

  • Titration: Test a wider antibody dilution range (1:200-1:2000) to find optimal signal-to-noise ratio

  • Incubation conditions: Compare overnight 4°C vs. room temperature incubations

  • Blocking agents: Try different blocking buffers (BSA vs. casein vs. commercial alternatives)

  • Secondary antibody selection: Test different detection systems (standard HRP vs. signal amplification systems)

• Signal verification approaches:

  • Kinase manipulation: Compare samples with and without CDK1 inhibitor treatment

  • Dephosphorylation controls: Treat parallel samples with lambda phosphatase

  • Peptide competition: Pre-incubate antibody with phospho-S425 peptide vs. non-phospho peptide

  • Antibody comparison: If available, test alternative phospho-S425 antibodies from different manufacturers

• Data interpretation guidelines:

  • Expected pattern: Strong signal in mitotic samples, minimal signal in G1/S phases

  • Molecular weight confirmation: CEP55 should appear at approximately 54-55 kDa

  • Positive controls: Include known mitotic cell extracts (e.g., nocodazole-treated HeLa cells)

  • Quantification approach: Normalize phospho-signal to total CEP55 rather than housekeeping proteins

By methodically implementing these strategies, researchers can significantly improve the consistency and reliability of phospho-CEP55 (S425) detection in experimental samples.

How should researchers interpret differences in CEP55 S425 phosphorylation patterns between cancer and normal cells?

When analyzing differences in CEP55 S425 phosphorylation between cancer and normal cells, researchers should consider this interpretive framework:

• Baseline expression considerations:

  • CEP55 is frequently upregulated in cancer cells, particularly in colon cancer (hence its alternative name URCC6 - Up-Regulated in Colon Cancer 6)

  • When comparing phosphorylation levels, it's essential to normalize phospho-S425 signal to total CEP55 protein rather than solely to loading controls

  • Calculate phosphorylation stoichiometry (ratio of phosphorylated to total protein) to distinguish between increased phosphorylation versus increased total protein

• Cell cycle distribution effects:

  • Cancer cells often have altered cell cycle profiles compared to normal cells

  • Higher mitotic index in cancer cell populations would naturally result in increased S425 phosphorylation

  • Control for this by:

    • Comparing synchronized populations at specific cell cycle phases

    • Using flow cytometry to quantify phospho-S425 signal alongside DNA content

    • Performing single-cell analyses with immunofluorescence to correlate phosphorylation with cell cycle markers

• Kinase activity alterations in cancer:

  • CDK1 (the kinase responsible for S425 phosphorylation) is frequently dysregulated in cancer

  • Evaluate whether altered S425 phosphorylation correlates with CDK1 activity markers

  • Test if CDK1 inhibitors normalize phosphorylation differences between cancer and normal cells

• Relationship to p53 status:

  • Research indicates a hierarchical regulation of CEP55 through a p53-PLK1-CEP55 axis

  • P53 inactivation (common in cancers) may indirectly affect CEP55 phosphorylation through altered PLK1 levels

  • Compare cells with differing p53 status to determine if this pathway explains observed phosphorylation differences

• Functional correlation with chromosomal instability:

  • CEP55 levels correlate with chromosomal instability (CIN) in ovarian and breast cancer cells

  • Examine whether altered S425 phosphorylation correlates with measures of CIN such as:

    • Frequency of misaligned chromosomes

    • Micronuclei formation rates

    • Aneuploidy levels

    • Microtubule stability markers (detyrosinated tubulin)

• Therapeutic implications:

  • If altered S425 phosphorylation contributes to cancer phenotypes, consider:

    • Whether CDK1 inhibitors might specifically target cells with aberrant CEP55 phosphorylation

    • If phosphorylation status could serve as a biomarker for sensitivity to anti-mitotic drugs

    • Whether combination therapies targeting both CEP55 and its phosphorylation regulators might be effective

This comprehensive interpretation approach allows researchers to distinguish mechanistic differences in phosphorylation from secondary effects of altered cell cycle or expression levels .

What methodological variations should be considered when comparing phospho-CEP55 (S425) antibodies from different manufacturers?

When comparing phospho-CEP55 (S425) antibodies from different manufacturers, researchers should consider these methodological variations to ensure accurate comparisons:

• Immunogen design differences:
  Based on the search results, different manufacturers use slightly different immunogen strategies:

  • Most use "synthesized phospho-peptide around the phosphorylation site of human CEP55 (phospho Ser425)"

  • The exact length and sequence of these peptides likely vary between manufacturers

  • Some may include carrier proteins while others use pure peptides

  Methodological approach: Request detailed immunogen sequence information from manufacturers to assess epitope differences.

• Antibody production and purification methods:
  Different production processes can affect specificity and sensitivity:

  • Most are purified via affinity chromatography using epitope-specific immunogen

  • Some undergo additional purification using sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns

  • Host animals and immunization protocols may differ

  Methodological approach: Compare antibodies using identical samples and protocols to control for methodological variables.

• Validation metrics comparison:
  Evaluate the depth of validation provided by each manufacturer:

  • Some provide extensive validation in multiple applications (WB, IHC, IF, ELISA)

  • Others may have validated only in specific applications

  • Validation in your specific experimental system may be limited

  Methodological approach: Create a validation panel with appropriate controls (phosphatase treatment, S425A mutants) to test all antibodies simultaneously.

• Cross-reactivity profiles:
  Assess potential cross-reactivity differences:

  • Compare reactivity with related phosphorylation sites (e.g., S428)

  • Test reactivity with close homologs of CEP55

  • Evaluate species cross-reactivity claims (human, mouse, rat)

  Methodological approach: Include parallel Western blots with recombinant phosphorylated and non-phosphorylated CEP55, and CEP55 with different phosphorylation combinations.

• Application-specific optimization requirements:
  Different antibodies may require different optimizations for each application:

  Application	Optimization Variables
  Western Blot	Dilution ranges vary (1:500-2000)
  IHC	Different recommended dilutions (1:100-1:300)
  IF	May require specific fixation methods
  ELISA	Substantial dilution differences (1:20000)

  Methodological approach: Create optimization matrices for each antibody and application to determine optimal conditions before comparison.

• Buffer composition effects:
  Most antibodies are formulated similarly but with potential variations:

  • Most contain "PBS with 50% glycerol, 0.5% BSA and 0.02% sodium azide"

  • Minor formulation differences could affect performance

  Methodological approach: Test antibody performance in different blocking buffers and diluents to identify optimal conditions for each.

By systematically addressing these methodological variations, researchers can develop a standardized comparison protocol that accounts for antibody-specific differences and ensures fair evaluation of performance across manufacturers .

How might studying CEP55 S425 phosphorylation contribute to understanding neurodevelopmental disorders?

Studying CEP55 S425 phosphorylation in neurodevelopmental contexts offers promising insights into pathological mechanisms, as evidenced by recent discoveries:

• CEP55's critical role in brain development:
  Recent research has identified crucial functions of CEP55 in neural development:

  • CEP55 is expressed in embryonic brain, particularly in the ganglionic eminence

  • It's also found in fetal brain tissues and multinucleate neurons in the temporal cortex

  • Its expression persists in adult brain and cerebellum

  • A severe human embryonic pathology called MARCH (multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly) is associated with CEP55 C-terminal truncation

• Potential roles of S425 phosphorylation in neuronal division and differentiation:
  The phosphorylation of CEP55 at S425 could be particularly significant in neural contexts:

  • Neural progenitor proliferation requires precise control of centrosome dynamics and cytokinesis

  • S425 phosphorylation controls CEP55 dissociation from centrosomes at the G2/M boundary

  • Disruptions to this phosphorylation could alter the balance between symmetric and asymmetric divisions, crucial for proper neurogenesis

  • The presence of multinucleated neurons in MARCH syndrome suggests cytokinesis defects that might relate to phosphorylation abnormalities

• Connections to microtubule regulation in neurons:
  CEP55's role in microtubule stability has particular relevance for neurons:

  • CEP55 stabilizes microtubules and increases polymerization rates by approximately 4-fold

  • Neurons rely heavily on stable microtubules for both development and function

  • S425 phosphorylation-dependent localization of CEP55 might contribute to differential microtubule stability in neuronal compartments

  • This could influence neuronal migration, axon guidance, and dendritic arborization

• Methodological approaches for neural investigations:
  Investigating S425 phosphorylation in neural contexts requires specialized approaches:

  • Neural cell models: Use neural progenitors, differentiated neurons, and organoids to track phosphorylation

  • Developmental timing studies: Examine S425 phosphorylation across developmental stages

  • Spatial mapping: Implement immunohistochemistry with phospho-S425 antibodies to map phosphorylation patterns across brain regions

  • Function-specific assays: Develop assays connecting phosphorylation status to neural-specific outcomes like migration, neurite extension, and synaptogenesis

• Therapeutic implications:
  Understanding S425 phosphorylation in neural contexts could lead to novel therapeutic approaches:

  • Identifying small molecules that modulate CEP55 phosphorylation might be neuroprotective

  • Gene therapy approaches targeting phosphorylation-dependent functions might address developmental disorders

  • Biomarkers based on phosphorylation status could aid in earlier detection of neurodevelopmental conditions

This research direction connects fundamental cell biology mechanisms to complex neurodevelopmental outcomes, potentially yielding important insights into both normal development and pathological conditions .

What is the current understanding of CEP55 S425 phosphorylation in cancer progression and potential therapeutic applications?

The current understanding of CEP55 S425 phosphorylation in cancer reveals emerging mechanistic insights and therapeutic opportunities:

• Cancer-specific alterations in CEP55 expression and phosphorylation:
  CEP55 is frequently upregulated in multiple cancer types, with potential phosphorylation implications:

  • Originally identified as "Up-Regulated in Colon Cancer 6" (URCC6)

  • Overexpression reported in various cancers including ovarian, breast, and colon cancers

  • High CEP55 levels correlate with increased chromosomal instability (CIN) and aneuploidy

  • P53 inactivation (common in cancers) indirectly increases CEP55 expression through a p53-PLK1-CEP55 axis

• Mechanistic connections to cancer hallmarks:
  S425 phosphorylation of CEP55 affects multiple cancer-relevant processes:

  • Microtubule dynamics: CEP55 stabilizes microtubules, protecting them from depolymerization by 80% and increasing polymerization rates 4-fold

  • Chromosomal instability: High CEP55 levels promote chromosome misalignment and missegregation

  • Cytokinesis defects: Altered CEP55 phosphorylation can disrupt abscission, potentially leading to tetraploidy and genomic instability

  • Cell cycle progression: The phosphorylation-dependent localization pattern of CEP55 influences mitotic progression

• Experimental evidence in cancer models:
  Research has demonstrated functional significance in cancer contexts:

  • In ovarian cancer cell lines (OVCAR-8 and SKOV-3), CEP55 depletion decreases chromosomal instability

  • Similar results observed in triple-negative breast cancer cells (MDA-MB-231 and MDA-MB-468)

  • CEP55 depletion significantly increases the number of cells with properly aligned chromosomes

  • Re-expression of CEP55 reverses these effects, confirming specificity

• Therapeutic opportunities:
  Several potential therapeutic strategies emerge from our understanding of CEP55 S425 phosphorylation:

  • CDK1 inhibitors: Could disrupt S425 phosphorylation, potentially reducing CEP55-mediated effects

  • Synthetic lethality approaches: Cancer cells with high CEP55 might be more sensitive to drugs targeting mitotic spindles or cytokinesis

  • Combination therapies: Targeting both CEP55 and microtubule dynamics might synergistically reduce chromosomal instability

  • Biomarker applications: CEP55 phosphorylation status might predict response to anti-mitotic therapies

• Methodological considerations for cancer research:
  When studying CEP55 S425 phosphorylation in cancer contexts:

  • Compare phosphorylation stoichiometry rather than just total phosphorylation levels

  • Account for cell cycle distribution differences between cancer and normal cells

  • Consider the relationship between CEP55 phosphorylation and other cancer-associated alterations (p53 status, PLK1 levels)

  • Examine phosphorylation in patient-derived samples alongside established cell lines

This evolving understanding connects fundamental phosphorylation mechanisms to cancer biology, with promising implications for both mechanistic insights and therapeutic development .

How does CEP55 S425 phosphorylation interact with other post-translational modifications to create a regulatory code?

CEP55 S425 phosphorylation functions within a complex network of post-translational modifications (PTMs) that collectively create a sophisticated regulatory code:

• Hierarchical phosphorylation network:
  S425 phosphorylation operates within a defined phosphorylation cascade:

  • S425 and S428 are phosphorylated at the onset of mitosis, prior to S436 phosphorylation

  • S425/S428 phosphorylation is performed by CDK1 and ERK2 respectively

  • S436 is subsequently phosphorylated by PLK1

  • This creates a temporal sequence where each phosphorylation event builds upon previous modifications

  • S425/S428 phosphorylation is required for centrosome dissociation, while S436 phosphorylation regulates midbody recruitment timing

• Potential crosstalk with ubiquitination:
  Evidence suggests interaction between phosphorylation and ubiquitin-related mechanisms:

  • CEP55 contains two NEMO-like Ubiquitin-Binding Domains (UBDs)

  • These domains mediate protein-protein interactions essential for CEP55 function

  • Phosphorylation, particularly at S425, might regulate accessibility or binding affinity of these UBDs

  • The zinc-finger fold in CEP55 (residues 435-464) could be influenced by nearby phosphorylation events

• Regulation of protein stability through PTM interactions:
  Research demonstrates that CEP55 stability is regulated through interconnected PTMs:

  • CEP55 stability is negatively regulated by p53 through down-regulation of PLK1

  • Proteasome inhibitors (MG132) affect CEP55 levels, suggesting ubiquitin-mediated degradation

  • Phosphorylation likely influences recognition by the ubiquitin-proteasome machinery

  • A complete understanding requires examining how S425 phosphorylation affects protein half-life

• Structural consequences of phosphorylation:
  Phosphorylation likely induces conformational changes with functional consequences:

  • S425 phosphorylation may induce structural changes that expose or conceal binding interfaces

  • The coiled-coil domains of CEP55 form dimeric structures that could be regulated by phosphorylation

  • Structural studies suggest CEP55 forms parallel α-helical coiled-coil dimers, similar to NEMO

  • Phosphorylation might regulate oligomerization state or binding partner selection

• Research approaches to decipher the PTM code:
  Comprehensive analysis of the CEP55 PTM code requires integrated methods:

  • Mass spectrometry-based phosphoproteomics: To identify all phosphorylation sites and their stoichiometry

  • Proximity labeling techniques: To identify PTM-dependent interaction partners

  • Site-directed mutagenesis: Creating combinations of phospho-mimetic and phospho-resistant mutations

  • Structural studies: Examining how phosphorylation affects protein conformation

  • Real-time biosensors: To monitor PTM dynamics in living cells